» Articles » PMID: 32977853

Integrative Analysis of the Common Genetic Characteristics in Ovarian Cancer Stem Cells Sorted by Multiple Approaches

Overview
Journal J Ovarian Res
Publisher Biomed Central
Date 2020 Sep 26
PMID 32977853
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Ovarian cancer is the second fatal malignancy of the female reproductive system. Based on the cancer stem cell (CSC) theory, its poor prognosis of ovarian cancer attributed to tumor recurrence caused by CSCs. A variety of cell surface-specific markers have been employed to identify ovarian cancer stem cells (OCSCs). In this study, we attempted to explore the common feature in ovarian cancer stem cells sorted by multiple approaches.

Methods: We collected the gene expression profiles of OCSCs were from 5 public cohorts and employed R software and Bioconductor packages to establish differently expressed genes (DEGs) between OCSCs and parental cells. We extracted the integrated DEGs by protein-protein interaction (PPI) network construction and explored potential treatment by the Cellminer database.

Results: We identified and integrated the DEGs of OCSCs sorted by multiple isolation approaches. Besides, we identified OCSCs share characteristics in the lipid metabolism and extracellular matrix changes. Moreover, we obtained 16 co-expressed core genes, such as FOXQ1, MMP7, AQP5, RBM47, ETV4, NPW, SUSD2, SFRP2, IDO1, ANPEP, CXCR4, SCNN1A, SPP1 and IFI27 (upregulated) and SERPINE1, DUSP1, CD40, and IL6 (downregulated). Through correlation analysis, we screened out ten potential drugs to target the core genes.

Conclusion: Based on the comprehensive analysis of the genomic datasets with different sorting methods of OCSCs, we figured out the common driving genes to regulating OCSC and obtained ten new potential therapies for eliminating ovarian cancer stem cells. Hence, the findings of our study might have potential clinical significance.

Citing Articles

Downregulated Dual-Specificity Protein Phosphatase 1 in Ovarian Carcinoma: A Comprehensive Study With Multiple Methods.

Liang Z, He R, Luo J, Huang Z, Li J, Zhong L Pathol Oncol Res. 2022; 28:1610404.

PMID: 35911442 PMC: 9336223. DOI: 10.3389/pore.2022.1610404.


Wnt antagonist as therapeutic targets in ovarian cancer.

Y K, Perumalsamy N, Warrier S, Perumalsamy L, Dharmarajan A Int J Biochem Cell Biol. 2022; 145:106191.

PMID: 35272015 PMC: 7616886. DOI: 10.1016/j.biocel.2022.106191.


Overexpression Correlates with Poor Prognosis and Immune Infiltrates in Ovarian Cancer.

Lou J, Wei L, Wang H Int J Gen Med. 2022; 15:1743-1763.

PMID: 35221714 PMC: 8865762. DOI: 10.2147/IJGM.S351976.


Prediction of Key Candidate Genes for Platinum Resistance in Ovarian Cancer.

Guo K, Li L Int J Gen Med. 2021; 14:8237-8248.

PMID: 34815697 PMC: 8605930. DOI: 10.2147/IJGM.S338044.

References
1.
Reinhold W, Sunshine M, Varma S, Doroshow J, Pommier Y . Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60. Clin Cancer Res. 2015; 21(17):3841-52. PMC: 4558215. DOI: 10.1158/1078-0432.CCR-15-0335. View

2.
Lupia M, Angiolini F, Bertalot G, Freddi S, Sachsenmeier K, Chisci E . CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells. Stem Cell Reports. 2018; 10(4):1412-1425. PMC: 5998305. DOI: 10.1016/j.stemcr.2018.02.009. View

3.
Chae Y, Kim J . Cancer stem cell metabolism: target for cancer therapy. BMB Rep. 2018; 51(7):319-326. PMC: 6089865. DOI: 10.5483/bmbrep.2018.51.7.112. View

4.
Lupia M, Cavallaro U . Ovarian cancer stem cells: still an elusive entity?. Mol Cancer. 2017; 16(1):64. PMC: 5360065. DOI: 10.1186/s12943-017-0638-3. View

5.
Wang L, Mezencev R, Bowen N, Matyunina L, McDonald J . Isolation and characterization of stem-like cells from a human ovarian cancer cell line. Mol Cell Biochem. 2011; 363(1-2):257-68. DOI: 10.1007/s11010-011-1178-6. View